PMID- 37751119 OWN - NLM STAT- MEDLINE DCOM- 20231221 LR - 20240409 IS - 1591-9528 (Electronic) IS - 1591-8890 (Linking) VI - 23 IP - 8 DP - 2023 Dec TI - B cell repopulation trajectory after rituximab treatment in autoimmune diseases: a longitudinal observational study. PG - 4787-4795 LID - 10.1007/s10238-023-01186-y [doi] AB - To investigate B-cell repopulation trajectory and the associated factors in patients with autoimmune diseases (AIDs) who underwent rituximab (RTX) treatment. This is a retrospective study in a large tertiary medical center. Kaplan-Meier analysis and Cox regression were used to investigate factors associated with B-cell repopulation. Latent class trajectory modeling (LCTM) was employed to identify distinct B-cell repopulation trajectory longitudinally. A total of 224 patients were included, with a cumulative follow-up time of 193.6 person-years. Patients with antineutrophil cytoplasm antibody-associated vasculitis (AAV), connective tissue disease, and IgG4-related disease exhibited significant differences in B-cell repopulation time (p = 0.0055 by log-rank test). Multivariate Cox regression identified that higher levels of IgA (HR 1.21, 95%CI 1.01-1.45, p = 0.040) and concurrent glucocorticoid use (HR = 0.37,95%CI 0.20-0.67, p = 0.001) were associated with B-cell repopulation. The cluster showing prolonged B-cell depletion, identified by LCTM, had lower proportions of male (27% vs. 48.5%, p = 0.033), smoke history (17.6% vs. 38.7%, p = 0.025), higher proportions of AAV (44.3% vs. 15.2%, p = 0.004), RTX dose (p = 0.042), history of cyclophosphamide use (70.4% vs. 48.5%, p = 0.003), meanwhile glucocorticoid use (94.8% vs. 72.7%, p = 0.001). The trajectory of B-cell repopulation after RTX infusion in AIDs was heterogeneous. Certain factors were associated with B-cell repopulation, and a specific cluster of patients demonstrated prolonged B-cell depletion after RTX treatment. CI - (c) 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG. FAU - Nie, Yuxue AU - Nie Y AD - Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Li, Jingna AU - Li J AD - Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Wu, Di AU - Wu D AD - Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Yang, Yunjiao AU - Yang Y AD - Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Zhang, Li AU - Zhang L AD - Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Bai, Wei AU - Bai W AD - Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Jiang, Nan AU - Jiang N AD - Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Qiao, Lin AU - Qiao L AD - Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Huang, Can AU - Huang C AD - Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Zhou, Shuang AU - Zhou S AD - Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Tian, Xinping AU - Tian X AD - Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Li, Mengtao AU - Li M AD - Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Zeng, Xiaofeng AU - Zeng X AD - Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Peng, Linyi AU - Peng L AD - Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. drpenglinyi@163.com. FAU - Zhang, Wen AU - Zhang W AD - Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. zhangwen91@sina.com. LA - eng GR - 2022-PUMCH-A-041/National High Level Hospital Clinical Research Funding/ GR - 2022-PUMCH-C-006，2022-PUMCH-B-013/National High Level Hospital Clinical Research Funding/ GR - 82071839, 82271848/National Natural Science Foundation of China/ GR - CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005/CAMS Innovation Fund for Medical Sciences/ PT - Journal Article PT - Observational Study DEP - 20230926 PL - Italy TA - Clin Exp Med JT - Clinical and experimental medicine JID - 100973405 RN - 4F4X42SYQ6 (Rituximab) RN - 0 (Glucocorticoids) SB - IM MH - Humans MH - Male MH - Rituximab/therapeutic use MH - Retrospective Studies MH - Glucocorticoids/therapeutic use MH - *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy MH - *Autoimmune Diseases/drug therapy MH - Treatment Outcome OTO - NOTNLM OT - Autoimmune diseases OT - B cell OT - Rituximab OT - Trajectory EDAT- 2023/09/26 13:42 MHDA- 2023/12/21 06:42 CRDT- 2023/09/26 11:14 PHST- 2023/08/19 00:00 [received] PHST- 2023/08/31 00:00 [accepted] PHST- 2023/12/21 06:42 [medline] PHST- 2023/09/26 13:42 [pubmed] PHST- 2023/09/26 11:14 [entrez] AID - 10.1007/s10238-023-01186-y [pii] AID - 10.1007/s10238-023-01186-y [doi] PST - ppublish SO - Clin Exp Med. 2023 Dec;23(8):4787-4795. doi: 10.1007/s10238-023-01186-y. Epub 2023 Sep 26.